

# Impact of Infusion of an ApoA-IMilano HDL Mimetic on Regression of Coronary Atherosclerosis in Acute Coronary Syndrome patients: the MILANO-PILOT Study

**Purpose:** To study plaque regression using an apoA-IMilano HDL mimetic (MDCO-216) in patients with a recent ACS.

**Trial Design:** Proof of concept, phase 2, double-blinded, placebo-controlled. N=126; 22 sites, 5 countries; Recent ACS w/in 14 days; randomized to five 20 mg/kg infusions/ week of MDCO-216 or placebo. Intravascular ultrasound (IVUS) at baseline on one coronary artery and again at end of infusion.

**Primary Endpoint:** change in percent atheroma volume (PAV) from baseline to study's end.

Trial Results	Change in % Atheroma Volume (PAV)	P	Placebo vs. MDCO-216
Statin + placebo	-0.8	<0.001	P=0.10
Statin + MDCO-216	-0.5	0.11	

**Conclusions:** The ApoA-I HDL mimetic did not significantly change the percent atheroma volume for ACS patients in this pilot study.